Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS-233 SR for prevention of depressive relapse in MDD
NCT00075257Phase 3Completed
- Sponsor
- Pfizer
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing DVS-233 SR with Placebo (2 arms). Primary endpoints: Relapse rate of depressive symptoms and Time to relapse of depressive symptoms. Status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00075257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075257.